IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

Rhea-AI Summary

IntelGenx Technologies Corp. reported financial results for Q4 2023 and full-year 2023, highlighting revenue growth, reduced net comprehensive losses, and strategic partnerships. The company expects significant revenue generation in 2024 through product launches. Financially, Q4 revenue increased to $426,000, with a net comprehensive loss of $1.7 million. Full-year revenue reached $1.04 million, with a net comprehensive loss of $10.1 million. Recent developments include private placement financing, Regulation A offering, partnership expansions, and positive clinical trial results.

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

"We successfully executed against key strategic priorities in 2023, the most important of which was to lay the groundwork for our product pipeline and services portfolio to start generating significant revenues in 2024,” commented Dwight Gorham, IntelGenx’s CEO. “To that end, we expect that our commercial partner for RIZAFILM^®1, Gensco Pharma, will be launching the product in the United States in Q2-2024, an anticipated inflection point for our business.”

2023 Fourth Quarter Financial Summary:

• Revenue was $426,000, up from $173,000 in the 2022 fourth quarter.
• Net comprehensive loss was $1.7 million, down from $2.3 million in the fourth quarter of 2022.
• Adjusted EBITDA loss was $1.7 million, compared to $2.3 million in Q4-2022.
  

2023 Full-Year Financial Summary:

• Revenue was $1.04 million, compared to $950,000 in 2022.
• Net comprehensive loss was $10.1 million, down from $11.6 million in 2022.
• Adjusted EBITDA loss was $8.3 million, compared to $8.5 million in 2022.
  

Fourth Quarter and Recent Developments:

• Closed a non-brokered private placement financing with atai Life Sciences AG (“atai”) for aggregate gross proceeds of $750,000, and announced an amended and restated loan agreement (the “Loan Agreement”) with atai, pursuant to which IntelGenx received a first tranche of $1 million and is eligible to receive a second tranche of $1 million in future upon the achievement of a pre-defined milestone.

• Launched a Regulation A offering of up to 2 million shares of Series A Convertible Cumulative Preferred Stock, par value $0.00001 per share, at an offering price of $10.00 per share (the “Regulation A Offering”).²

• Entered into a further amendment to its November 2018 license, development and supply agreement with Tilray Brands Inc. (“Tilray”) for the co-development and commercialization of cannabinoid-infused VersaFilm^® products, and received an initial purchase order from Tilray for three SKUs (CBD20, THC10, THC10:CBD 10), with each SKU totalling 130,000 filmstrips.

• Entered into development and license agreements with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC for VetaFilm^®.

• Received approvals from the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre to conduct the ’MONTPARK’ Montelukast VersaFilm^® Phase 2 clinical trial in patients with Parkinson's Disease.

• Announced positive results from a proof-of-concept study, conducted through a research collaboration with the University of Prince Edward Island, that validated the advantages of administering drugs to pets via its VetaFilm^® platform.

• Announced changes to its Board, appointing Sahil Kirpekar, M.D., atai’s Chief Business Officer, and Ryan Barrett, atai’s Senior Vice President and General Counsel, as atai’s new designees.
  

Financial Results:

Total revenues for the three-month period ended December 31, 2023 amounted to $426,000, an increase of $253,000, or 146%, compared to $173,000 for the three-month period ended December 31, 2022. The change is mainly attributable to an increase in research and development (“R&D”) revenues. Operating costs and expenses were $2.4 million for the fourth quarter of 2023, versus $2.7 million for the corresponding three-month period of 2022. For Q4-2023, the Company had an operating loss of $2.0 million, down from $2.5 million for the comparable period of 2022. Net comprehensive loss was $1.7 million, or $0.01 per basic and diluted share, for the fourth quarter of 2023, compared to net comprehensive loss of $2.3 million, or $0.01 per basic and diluted share, for the comparable period of 2022.

Total revenues for the twelve-month period ended December 31, 2023 amounted to $1.04 million, representing an increase of $89,000, or 6%, compared to $950,000 for the year ended December 31, 2022. Operating costs and expenses were $10.5 million for the full year 2023, versus $10.4 million for the corresponding twelve-month period of 2022. For the twelve-month period of 2023, the Company had an operating loss of $9.5 million, compared to an operating loss of $9.4 million for the comparable period of 2022. Net comprehensive loss was $10.1 million, or $0.06 per basic and diluted share, for the twelve-month period of 2023, compared to net comprehensive loss of $11.6 million, or $0.07 per basic and diluted share, for the comparable period of 2022.

As at December 31, 2023, the Company's cash and short-term investments totalled $2.3 million. Subsequent to year-end, IntelGenx announced the launch of the Regulation A Share Offering and received $1 million pursuant to its Loan Agreement with atai.

Annual Filings:

The Company's annual report on Form 10-K and financial statements for the year ended December 31, 2023, as well as the 2024 Proxy Statement, will be filed with the United States Securities and Exchange Commission and the Canadian Securities regulatory authorities today, March 21, 2024.

Conference Call Details:

IntelGenx will host a conference call to discuss these 2022 fourth quarter and full year financial results today at 8:30 a.m. ET. The dial-in number for the conference call is (888) 506-0062 (Canada and the United States) or (973) 528-0011 (International); access code 321268. The call will be also be webcast live and archived on the Company's website at www.intelgenx.com under "Webcasts" in the Investors section.

¹ RIZAFILM^® is a Registered Trademark of Gensco^® Pharma Corporation.

² This press release does not constitute an offer to sell nor a solicitation of an offer to purchase any securities in any jurisdiction in which such an offer or solicitation is not authorized and does not constitute an offer within any jurisdiction to any person to whom such offer would be unlawful.

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm^®, DisinteQ^™, VetaFilm^® and transdermal VevaDerm^™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

Forward-Looking Information and Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Source: IntelGenx Technologies Corp.

For IntelGenx:

Stephen Kilmer
Investor Relations
(647) 872-4849
stephen@kilmerlucas.com

Or

Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

FAQ

What were IntelGenx's revenue and net comprehensive loss for Q4 2023?

IntelGenx reported revenue of $426,000 for Q4 2023, with a net comprehensive loss of $1.7 million.

What was IntelGenx's revenue for the full-year 2023?

IntelGenx's revenue for the full-year 2023 was $1.04 million.

What recent financial offerings did IntelGenx announce?

IntelGenx announced a private placement financing and a Regulation A offering.

With whom did IntelGenx expand its partnership for co-development and commercialization?

IntelGenx expanded its partnership with Tilray Brands Inc.

What clinical trial did IntelGenx receive approvals for?

IntelGenx received approvals for the 'MONTPARK' Montelukast VersaFilm® Phase 2 clinical trial in patients with Parkinson's Disease.